Format

Send to

Choose Destination
Virusdisease. 2020 Mar;31(1):28-37. doi: 10.1007/s13337-020-00570-6. Epub 2020 Mar 7.

Understanding of Zaire ebolavirus-human protein interaction for drug repurposing.

Author information

1
Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Pondicherry, 605014 India.

Abstract

The Ebola virus is a human aggressive pathogen causes Ebola virus disease that threatens public health, for which there is no Food Drug Administration approved medication. Drug repurposing is an alternative method to find the novel indications of known drugs to treat the disease effectively at low cost. The present work focused on understanding the host-virus interaction as well as host virus drug interaction to identify the disease pathways and host-directed drug targets. Thus, existing direct physical Ebola-human protein-protein interaction (PPI) was collected from various publicly available databases and also literature through manual curation. Further, the functional and pathway enrichment analysis for the proteins were performed using database for annotation, visualization, and integrated discovery and the enriched gene ontology biological process terms includes chromatin assembly or disassembly, nucleosome organization, nucleosome assembly. Also, the enriched Kyoto Encyclopedia of Genes and Genome pathway terms includes systemic lupus erythematosus, alcoholism, and viral carcinogenesis. From the PPI network, important large histone clusters and tubulin were observed. Further, the host-virus and host-virus-drug interaction network has been generated and found that 182 drugs are associated with 45 host genes. The obtained drugs and their interacting targets could be considered for Ebola treatment.

KEYWORDS:

Drug repurposing; Host–virus interaction; Protein–protein interaction; Zaire Ebola virus

PMID:
32206696
PMCID:
PMC7085497
[Available on 2021-03-01]
DOI:
10.1007/s13337-020-00570-6

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interests.

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center